for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Mallinckrodt PLC

MNK.N

Latest Trade

3.24USD

Change

0.15(+4.85%)

Volume

819,302

Today's Range

3.05

 - 

3.26

52 Week Range

1.43

 - 

27.30

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Mallinckrodt Reports Positive Phase 3 Results From CONFIRM Study Of Terlipressin

Nov 11 (Reuters) - Mallinckrodt Plc <MNK.N>::MALLINCKRODT PRESENTS POSITIVE PHASE 3 RESULTS FROM ITS CONFIRM STUDY OF TERLIPRESSIN IN PATIENTS WITH HEPATORENAL SYNDROME TYPE 1 (HRS-1) AT THE LIVER MEETING® 2019.STUDY SHOWED A STATISTICALLY SIGNIFICANT NUMBER OF PATIENTS ON TERLIPRESSIN ACHIEVED PRIMARY ENDPOINT OF VERIFIED HRS REVERSAL VERSUS PLACEBO.PLANS TO SUBMIT A NEW DRUG APPLICATION FOR HRS-1 TO U.S. FDA IN FIRST HALF OF 2020.

Mallinckrodt Says In Aug Co Got Subpoena From US SEC For Documents On Co's Dispute With US HHS, CMS Concerning Manufacturer Price For Co's Acthar Gel

Nov 5 (Reuters) - Mallinckrodt Plc <MNK.N>::MALLINCKRODT - IN AUG., GOT SUBPOENA FROM U.S. SEC FOR DOCUMENTS ON CO’S DISPUTE WITH U.S. HHS, CMS CONCERNING MANUFACTURER PRICE FOR CO’S ACTHAR GEL.MALLINCKRODT - SHOULD A BANKRUPTCY OCCURS, CO WOULD BE SUBJECT TO RISKS, UNCERTAINTIES THAT COULD ADVERSELY AFFECT ABILITY TO CONTINUE AS GOING CONCERN.

Mallinckrodt Q3 Adjusted Earnings Per Share $2.07

Mallinckrodt Plc <MNK.N>::REPORTS EARNINGS AND PIPELINE ADVANCEMENTS FOR THE THIRD QUARTER 2019 AND RAISES ADJUSTED DILUTED EARNINGS PER SHARE GUIDANCE RANGE FOR 2019.Q3 ADJUSTED EARNINGS PER SHARE $2.07.Q3 LOSS PER SHARE $0.01 FROM CONTINUING OPERATIONS.Q3 SALES $743.7 MILLION.SEES FY 2019 ADJUSTED EARNINGS PER SHARE $8.50 TO $8.70.RAISED 2019 FISCAL YEAR ADJUSTED DILUTED EPS GUIDANCE RANGE TO $8.50 TO $8.70 (PREVIOUSLY $8.40 TO $8.70).FY2019 EARNINGS PER SHARE VIEW $8.48 -- REFINITIV IBES DATA.MALLINCKRODT - WORKING TO RESOLVE NEAR TERM UNCERTAINTIES IN BUSINESS, PARTICULARLY OPIOID LITIGATION AND SEPARATION OF OUR SPECIALTY GENERICS SEGMENT.SPECIALTY BRANDS SEGMENT NET SALES IN Q3 WERE $580.4 MILLION, DOWN 9.3%.SPECIALTY GENERICS SEGMENT REPORTED Q3 NET SALES OF $163.3 MILLION, UP 2.1%.

Mallinckrodt Says Uvadex Received Approval In Australia For Use with Therakos Photopheresis System

Oct 31 (Reuters) - Mallinckrodt Plc <MNK.N>::MALLINCKRODT ANNOUNCES UVADEX® (METHOXSALEN) APPROVED IN AUSTRALIA FOR USE WITH THE THERAKOS® CELLEX® PHOTOPHERESIS SYSTEM FOR TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD) AND SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA (CTCL) IN ADULTS.MALLINCKRODT PLC - UVADEX HAS RECEIVED REGULATORY APPROVAL IN AUSTRALIA FOR EXTRACORPOREAL ADMINISTRATION WITH THERAKOS PHOTOPHERESIS SYSTEM.

Armistice Capital Reports 8.5% Passive Stake In Mallinckrodt As Of Oct. 2

Oct 16 (Reuters) - Mallinckrodt Plc <MNK.N>::ARMISTICE CAPITAL, LLC REPORTS A 8.5% PASSIVE STAKE IN MALLINCKRODT PLC AS OF OCT 2 - SEC FILING.

Mallinckrodt Announces Positive data for Acthar Gel in Multiple Sclerosis Relapse Patients

Oct 1 (Reuters) - Mallinckrodt Plc <MNK.N>::MALLINCKRODT ANNOUNCES POSITIVE TOP-LINE FINDINGS FROM ITS OBSERVATIONAL REGISTRY ASSESSING RELAPSE RECOVERY IN MULTIPLE SCLEROSIS RELAPSE PATIENTS TREATED WITH ACTHAR® GEL (REPOSITORY CORTICOTROPIN INJECTION).MALLINCKRODT PLC - RESPONSE WAS SUSTAINED AT 6 MONTHS.MALLINCKRODT PLC - RESULTS FOR MAIN SUBSETS OF PATIENTS ARE HIGHLY STATISTICALLY SIGNIFICANT FOR ALL EFFICACY ENDPOINTS.MALLINCKRODT PLC - ANALYSIS SHOWED PATIENTS TREATED WITH ACTHAR GEL REPORTED SIGNIFICANT IMPROVEMENTS IN THEIR MS RELAPSE SYMPTOMS.MALLINCKRODT PLC - RESULTS FOR MAIN SUBSETS OF PATIENTS ARE HIGHLY STATISTICALLY SIGNIFICANT FOR ALL EFFICACY ENDPOINTS.MALLINCKRODT PLC - ADVERSE EVENTS WERE CONSISTENT WITH THOSE IN PREVIOUS TRIALS OF ACTHAR GEL.

Mallinckrodt Announces Positive Top-Line Results From Pivotal Phase 3 Clinical Trial Of Stratagraft Regenerative Tissue In Patients With Deep Partial-Thickness Thermal Burns

Sept 23 (Reuters) - Mallinckrodt Plc <MNK.N>::MALLINCKRODT ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PIVOTAL PHASE 3 CLINICAL TRIAL OF STRATAGRAFT® REGENERATIVE TISSUE IN PATIENTS WITH DEEP PARTIAL-THICKNESS THERMAL BURNS.MALLINCKRODT PLC - STUDY MET BOTH CO-PRIMARY ENDPOINTS WITH HIGH STATISTICAL SIGNIFICANCE.MALLINCKRODT PLC - COMPANY PLANS TO SUBMIT BIOLOGICS LICENSE APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION IN FIRST HALF OF 2020.MALLINCKRODT PLC - STUDY DEMONSTRATED AUTOGRAFT SPARING AND DURABLE WOUND CLOSURE AT THREE MONTHS WITH STRATAGRAFT.

Fitch Says U.S. Collateralized Loan Obligations Fairly Insulated From Pharma Sector's Opioid Issue

Sept 20 (Reuters) - Fitch::FITCH SAYS U.S. COLLATERALIZED LOAN OBLIGATIONS FAIRLY INSULATED FROM PHARMA SECTOR'S OPIOID ISSUE.FITCH - VIEWS SETTLEMENT AGREEMENTS REACHED BY MALLINCKRODT, ENDO AS POSITIVE DEVELOPMENTS BUT THIS DOES NOT ELIMINATE ALL PENDING OPIOID LITIGATION.FITCH - VIEWS EFFECT OF DRUG PRICE FIXING LITIGATION RISK ON FINANCIAL PROFILES COULD BE LESS MATERIAL THAN OPIOID RELATED LAWSUITS &/OR SETTLEMENTS.

Mallinckrodt CEO Sees Pathway To Global Settlement For All Co's Opioid Litigation

Sept 10 (Reuters) - Mallinckrodt Plc <MNK.N>::MALLINCKRODT CEO SAYS CO SEES PATHWAY TO GLOBAL SETTLEMENT FOR ALL OPIOID LITIGATION - CONFERENCE.MALLINCKRODT CEO SAYS CO SPENDS ABOUT $40 MILLION A YEAR ON DEALING WITH OPIOID LAWSUITS - CONFERENCE.

Mallinckrodt Agrees To Sell Biovectra Inc. To H.I.G. Capital For $250 Million

Sept 10 (Reuters) - Mallinckrodt Plc <MNK.N>::PRESS RELEASE - MALLINCKRODT AGREES TO SELL BIOVECTRA INC. TO H.I.G. CAPITAL FOR $250 MILLION.MALLINCKRODT PLC - DEAL FOR FOR APPROXIMATELY $250 MILLION.MALLINCKRODT PLC - NOT ANTICIPATED THAT SALE WILL HAVE ANY MATERIAL TAX IMPACT TO MALLINCKRODT.MALLINCKRODT - DEAL CONSIDERATION INCLUDES FIXED CONSIDERATION OF $175 MILLION, COMPRISED OF AN UPFRONT PAYMENT OF $135 MILLION & LONG-TERM NOTE FOR $40 MILLION.MALLINCKRODT PLC - COMPANY INTENDS TO USE PROCEEDS FROM DIVESTITURE CONSISTENT WITH ITS PREVIOUSLY DISCLOSED CAPITAL ALLOCATION PRIORITIES.MALLINCKRODT PLC - DEAL CONSIDERATION INCLUDES CONTINGENT PAYMENTS OF UP TO $75 MILLION.MALLINCKRODT- TRANSACTION IS ANTICIPATED TO INCLUDE ALL OF BIOVECTRA'S SITES IN PRINCE EDWARD ISLAND, NOVA SCOTIA, CANADA, AS WELL AS ITS EMPLOYEE BASE.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up